A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Buparlisib (Primary) ; Everolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Mar 2017 Planned End Date changed from 1 Apr 2018 to 1 May 2018.
- 01 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018.
- 01 Mar 2017 Status changed from recruiting to active, no longer recruiting.